STOCK TITAN

[Form 4] CHEMED CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Chemed Corp (CHE) reported an insider equity award. On 10/21/2025, the company granted its VP and Chief Legal Officer a stock option for 15,017 shares at an exercise price of $443.79 per share, expiring on 10/21/2030. The option vests in three equal annual installments commencing 10/21/2026. After this grant, the reporting person beneficially owned 38,067 derivative securities, held directly.

Chemed Corp (CHE) ha riportato una assegnazione di azioni da parte di insider. Il 21/10/2025, l'azienda ha concesso al suo vicepresidente e direttore legale una stock option per 15.017 azioni ad un prezzo di esercizio di $443,79 per azione, con scadenza il 21/10/2030. L'opzione maturerà in tre rate annuali uguali a partire dal 21/10/2026. Dopo questa assegnazione, la persona segnalata possedeva beneficiariamente 38.067 strumenti derivati, detenuti direttamente.

Chemed Corp (CHE) informó una adjudicación de acciones para insiders. El 21/10/2025, la empresa concedió a su vicepresidente y director legal una opción de compra de 15,017 acciones a un precio de ejercicio de $443.79 por acción, con vencimiento el 21/10/2030. La opción se consolidará en tres cuotas anuales iguales a partir del 21/10/2026. Después de esta adjudicación, la persona reportante poseía beneficiosamente 38,067 valores derivados, mantenidos directamente.

Chemed Corp (CHE) 내부자 주식 보상에 대해 보고했습니다. 2025년 10월 21일, 회사는 부사장 겸 최고법무책임자에게 15,017주의 주식매수를 부여했고, 행사 가격은 주당 $443.79이며 만료일은 2030년 10월 21일입니다. 옵션은 2026년 10월 21일부터 매년 동등한 3회로 vest됩니다. 이 부여 후, 보고자(공개정보제공자)는 38,067개의 파생 증권을 직접 보유하게 되었습니다.

Chemed Corp (CHE) a annoncé une attribution d'actions pour initiés. Le 21/10/2025, l'entreprise a accordé à son vice-président et directeur juridique une option d'achat sur 15 017 actions à un prix d'exercice de $443,79 par action, expirant le 21/10/2030. L'option vestira en trois versements annuels égaux à partir du 21/10/2026. Après cette attribution, la personne déclarant détenait avantageusement 38 067 valeurs dérivées, détenues directement.

Chemed Corp (CHE) meldete eine Insider-Aktienzuteilung. Am 21.10.2025 gewährte das Unternehmen seinem Vizepräsidenten und Chief Legal Officer eine Aktienoption über 15.017 Aktien zu einem Ausübungspreis von $443,79 pro Aktie, die am 21.10.2030 verfällt. Die Option vestet in drei gesicherten jährlichen Raten, beginnend am 21.10.2026. Nach dieser Zuteilung hielt die meldende Person vorteilhaft 38.067 Derivatewerte, direkt gehalten.

Chemed Corp (CHE) أبلغت عن منحة أسهم للمطلعين. في 21/10/2025، منحت الشركة نائب رئيسها وكبير المستشارين القانونيين خيار أسهم لـ 15,017 سهمًا بسعر تنفيذ قدره $443.79 للسهم، منتهية صلاحيته في 21/10/2030. يستحق الخيار على ثلاث دفعات سنوية متساوية ابتداءً من 21/10/2026. بعد هذه المنحة، امتلك الشخص المبلّغ عنه بشكل مستفاد 38,067 ورقة مشتقة، مملوكة مباشرة.

Positive
  • None.
Negative
  • None.

Insights

Routine Form 4 option grant; neutral governance event.

Chemed disclosed a stock option grant of 15,017 shares at an exercise price of $443.79, expiring on 10/21/2030. This is standard executive compensation and does not itself change operating performance.

The award vests in three equal tranches starting 10/21/2026, aligning incentives over multiple years. Any share issuance occurs only upon exercise at or above the strike price.

Following the grant, the insider reports 38,067 derivative securities held directly. Market impact depends on future exercises and remains typical for such awards.

Chemed Corp (CHE) ha riportato una assegnazione di azioni da parte di insider. Il 21/10/2025, l'azienda ha concesso al suo vicepresidente e direttore legale una stock option per 15.017 azioni ad un prezzo di esercizio di $443,79 per azione, con scadenza il 21/10/2030. L'opzione maturerà in tre rate annuali uguali a partire dal 21/10/2026. Dopo questa assegnazione, la persona segnalata possedeva beneficiariamente 38.067 strumenti derivati, detenuti direttamente.

Chemed Corp (CHE) informó una adjudicación de acciones para insiders. El 21/10/2025, la empresa concedió a su vicepresidente y director legal una opción de compra de 15,017 acciones a un precio de ejercicio de $443.79 por acción, con vencimiento el 21/10/2030. La opción se consolidará en tres cuotas anuales iguales a partir del 21/10/2026. Después de esta adjudicación, la persona reportante poseía beneficiosamente 38,067 valores derivados, mantenidos directamente.

Chemed Corp (CHE) 내부자 주식 보상에 대해 보고했습니다. 2025년 10월 21일, 회사는 부사장 겸 최고법무책임자에게 15,017주의 주식매수를 부여했고, 행사 가격은 주당 $443.79이며 만료일은 2030년 10월 21일입니다. 옵션은 2026년 10월 21일부터 매년 동등한 3회로 vest됩니다. 이 부여 후, 보고자(공개정보제공자)는 38,067개의 파생 증권을 직접 보유하게 되었습니다.

Chemed Corp (CHE) a annoncé une attribution d'actions pour initiés. Le 21/10/2025, l'entreprise a accordé à son vice-président et directeur juridique une option d'achat sur 15 017 actions à un prix d'exercice de $443,79 par action, expirant le 21/10/2030. L'option vestira en trois versements annuels égaux à partir du 21/10/2026. Après cette attribution, la personne déclarant détenait avantageusement 38 067 valeurs dérivées, détenues directement.

Chemed Corp (CHE) meldete eine Insider-Aktienzuteilung. Am 21.10.2025 gewährte das Unternehmen seinem Vizepräsidenten und Chief Legal Officer eine Aktienoption über 15.017 Aktien zu einem Ausübungspreis von $443,79 pro Aktie, die am 21.10.2030 verfällt. Die Option vestet in drei gesicherten jährlichen Raten, beginnend am 21.10.2026. Nach dieser Zuteilung hielt die meldende Person vorteilhaft 38.067 Derivatewerte, direkt gehalten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Judkins Brian C

(Last) (First) (Middle)
255 EAST FIFTH STREET
SUITE 2600

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHEMED CORP [ CHE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP and Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy with tandem tax withholding) $443.79 10/21/2025 A 15,017 (1) 10/21/2030 Capital Stock 15,017 $443.79 38,067 D
Explanation of Responses:
1. Vesting in three equal annual installments commencing 10/21/2026
Brian C. Judkins 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Chemed (CHE) disclose in this Form 4?

A stock option grant of 15,017 shares at an exercise price of $443.79 to the VP & Chief Legal Officer on 10/21/2025.

What is the vesting schedule for the CHE stock options?

The option vests in three equal annual installments commencing 10/21/2026.

When do the reported Chemed stock options expire?

The options expire on 10/21/2030.

How many derivative securities does the insider hold after the grant?

The reporting person beneficially owned 38,067 derivative securities following the transaction.

What is the ownership form of the reported securities?

The filing indicates Direct (D) ownership.

What role does the reporting person hold at Chemed (CHE)?

They are an Officer, serving as VP and Chief Legal Officer.
Chemed Corp

NYSE:CHE

CHE Rankings

CHE Latest News

CHE Latest SEC Filings

CHE Stock Data

6.34B
14.29M
1.98%
97.98%
2.82%
Medical Care Facilities
Services-home Health Care Services
Link
United States
CINCINNATI